{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T17:32:37Z","timestamp":1648834357653},"reference-count":0,"publisher":"Portland Press Ltd.","issue":"3","content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[1978,9,1]]},"abstract":"<jats:p>1. Spiral strips of human digital arteries have been studied in vitro to investigate whether dl-propranolol, d-propranolol, oxprenolol and labetalol have peripheral vascular effects in man.<\/jats:p>\n               <jats:p>2. Labetalol was a potent inhibitor of contractile responses to noradrenaline, but had less effect on responses to 5-hydroxytryptamine and barium chloride.<\/jats:p>\n               <jats:p>3. dl-and d-propranolol were equally effective inhibitors of responses to barium chloride. They were only weak antagonists of noradrenaline responses, but stronger, non-competitive antagonists of 5-hydroxytryptamine responses.<\/jats:p>\n               <jats:p>4. Oxprenolol was only a weak inhibitor of the responses to both noradrenaline and 5-hydroxytryptamine and had little effect on responses to barium chloride.<\/jats:p>\n               <jats:p>5. It is concluded that labetalol has specific \u03b1-adrenoreceptor-blocking properties, which are probably relevant to its therapeutic action in man. Propranolol has non-specific inhibitory effects on vascular smooth muscle, which might contribute to its hypotensive activity at high concentrations, but oxprenolol has only slight peripheral effects that are probably therapeutically insignificant.<\/jats:p>","DOI":"10.1042\/cs0550235","type":"journal-article","created":{"date-parts":[[2015,8,7]],"date-time":"2015-08-07T10:34:59Z","timestamp":1438943699000},"page":"235-240","update-policy":"http:\/\/dx.doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effects of the \u03b2-Receptor Antagonists Propranolol, Oxprenolol and Labetalol on Human Vascular Smooth-Muscle Contraction"],"prefix":"10.1042","volume":"55","author":[{"given":"R. F. W.","family":"Moulds","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Melbourne, Therapeutics, The Royal Melbourne Hospital, Victoria, Australia"},{"name":"Department of Clinical Pharmacology and Therapeutics, The Royal Melbourne Hospital, Victoria, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. A.","family":"Jauernig","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Melbourne, Therapeutics, The Royal Melbourne Hospital, Victoria, Australia"},{"name":"Department of Clinical Pharmacology and Therapeutics, The Royal Melbourne Hospital, Victoria, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. D.","family":"Hobson","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Melbourne, Therapeutics, The Royal Melbourne Hospital, Victoria, Australia"},{"name":"Department of Clinical Pharmacology and Therapeutics, The Royal Melbourne Hospital, Victoria, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Shaw","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Melbourne, Therapeutics, The Royal Melbourne Hospital, Victoria, Australia"},{"name":"Department of Clinical Pharmacology and Therapeutics, The Royal Melbourne Hospital, Victoria, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"288","container-title":["Clinical Science"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/portlandpress.com\/clinsci\/article-pdf\/55\/3\/235\/451284\/cs0550235.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/portlandpress.com\/clinsci\/article-pdf\/55\/3\/235\/451284\/cs0550235.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,28]],"date-time":"2019-10-28T00:37:21Z","timestamp":1572223041000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/clinsci\/article\/55\/3\/235\/73986\/Effects-of-the-%CE%B2Receptor-Antagonists-Propranolol"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1978,9,1]]},"references-count":0,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1978,9,1]]}},"URL":"https:\/\/doi.org\/10.1042\/cs0550235","relation":{},"ISSN":["0143-5221"],"issn-type":[{"value":"0143-5221","type":"print"}],"subject":[],"published":{"date-parts":[[1978,9,1]]}}}